Candel Therapeutics Inc., a clinical-stage biopharmaceutical company, has appointed Maha Radhakrishnan, M.D., to its Board of Directors, effective June 4, 2025. This strategic addition comes as Candel progresses towards its Biologics License Application submission for CAN-2409 in intermediate-to-high-risk prostate cancer, expected in Q4 2026. Dr. Radhakrishnan's extensive industry experience is anticipated to support Candel's efforts in advancing its oncology programs towards potential approval and commercial development.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.